A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate

Part of paid clinical trials in Basking Ridge, New Jersey.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT06941480
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Neuroendocrine Carcinoma
  • Neuroendocrine Carcinoma of Lung
  • Neuroendocrine Carcinoma of Prostate
  • Neuroendocrine Tumor of the Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PET/CT — DIAGNOSTIC_TEST
    Participants will undergo 89Zr-DFO-SC16.56 Ab PET/CT
  • 177Lu-DTPA-SC16.56 — BIOLOGICAL
    177Lu-DTPA-SC16.56, to be administered within 2 weeks of the PET/CT

Study Details

The purpose of this study is to find out whether 177Lu-DTPA-SC16.56 is a safe treatment for people with small-cell lung cancer or neuroendocrine prostate cancer

Key Dates

Start date
Jun 30, 2026
Status verified
Apr 2026
Primary completion
May 31, 2030
Completion
May 31, 2030

Study Design

Enrollment
12 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Participants with neuroendocrine carcinomas of the lung
  • Experimental: Participants with neuroendocrine prostate cancer

Primary Outcome Measure

Maximum tolerated dose of 177Lu-DTPA-SC16.56 [ Time Frame: Up to 36 months ]

Central Contacts

Locations (7)

FacilityCityStateZIPSite coordinators
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)Basking RidgeNew Jersey07920
Lisa Bodei, MD, PhD
212-639-7373
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)MiddletownNew Jersey07748
Lisa Bodei, MD, PhD
212-639-7373
Memorial Sloan Kettering Bergen (Limited Protocol Activities)MontvaleNew Jersey07645
Lisa Bodei, MD, PhD
212-639-7373
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities )CommackNew York11725
Lisa Bodei, MD, PhD
212-639-7373
Memorial Sloan Kettering Westchester (Limited Protocol Activities)HarrisonNew York10604
Lisa Bodei, MD, PhD
212-639-7373
Memorial Sloan Kettering Cancer Center (All Protocol Activities)New YorkNew York10065
Lisa Bodei, MD, PhD
212-639-7373
Lisa Bodei, MD (PRINCIPAL_INVESTIGATOR)
Memorial Sloan Kettering Nassau (Limited protocol activities)Rockville CentreNew York11553
Lisa Bodei, MD, PhD
212-639-7373

Find similar trials in Basking Ridge, NJ

By condition
Neuroendocrine tumors
By specialty
Oncology
By research site
Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities)· Basking Ridge, NJMemorial Sloan Kettering Monmouth (Limited Protocol Activities)· Middletown, NJMemorial Sloan Kettering Bergen (Limited Protocol Activities)· Montvale, NJMemorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities )· Commack, NYMemorial Sloan Kettering Westchester (Limited Protocol Activities)· Harrison, NYMemorial Sloan Kettering Cancer Center (All Protocol Activities)· New York, NY

Related Studies